Antimicrobial
Oxazolidinones (linezolid)
50S initiation-complex inhibitor for Gram-positives
ox-uh-zoe-LID-uh-nones
High-yield clue
Linezolid blocks formation of the 70S initiation complex and covers resistant Gram-positives including MRSA and VRE.
Overview
A fully synthetic protein-synthesis class (linezolid, tedizolid) studied for binding the 23S rRNA of the 50S subunit and blocking assembly of the 70S initiation complex.
Classification
- Protein-synthesis inhibitor
- Binds 23S rRNA of 50S subunit
- Bacteriostatic (bactericidal for streptococci concept)
- Synthetic class
Lab & identification clues
- Prevents 70S initiation complex formation
- Resistance via 23S rRNA / cfr mutations concept
- Full oral bioavailability vocabulary
Associations
- MRSA and VRE coverage vocabulary
- Serotonin / monoamine oxidase interaction concept
- Marrow suppression with prolonged use concept
Commonly confused with
- Lincosamides (clindamycin)
- Macrolides
Frequently asked questions
What is Oxazolidinones (linezolid)?
A fully synthetic protein-synthesis class (linezolid, tedizolid) studied for binding the 23S rRNA of the 50S subunit and blocking assembly of the 70S initiation complex.
What is the high-yield clue for Oxazolidinones (linezolid)?
Linezolid blocks formation of the 70S initiation complex and covers resistant Gram-positives including MRSA and VRE.
What is Oxazolidinones (linezolid) associated with?
Oxazolidinones (linezolid) is associated with MRSA and VRE coverage vocabulary, Serotonin / monoamine oxidase interaction concept, and Marrow suppression with prolonged use concept.
What is Oxazolidinones (linezolid) commonly confused with?
Oxazolidinones (linezolid) is commonly confused with Lincosamides (clindamycin) and Macrolides.
Original mechanism summary for microbiology study. Sources checked: CDC antimicrobial-resistance guidance, NCBI Bookshelf Medical Microbiology, and standard coursework frameworks; reviewed 2026-06. Covers class, mechanism, and resistance vocabulary only; no prescribing, dosing, or patient-specific treatment guidance.